Related Experiment Video

Updated: Oct 18, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K

TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer

Yixuan Liu1,2,3, Keyu Zhu1,2, Xiaolin Guan1,2

  • 1Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No.270, Dong'An Road, Xuhui District, Shanghai, 200032, China.

Journal of Ovarian Research
|October 2, 2021
PubMed
Abstract

Insights

Threonine and tyrosine kinase (TTK) is upregulated in cisplatin-resistant ovarian cancer. Inhibiting TTK may restore chemotherapy sensitivity, offering a new therapeutic target for ovarian cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ovarian cancer prognosis is poor due to drug resistance and recurrence.
  • Cisplatin is a key chemotherapy agent, but resistance mechanisms are unclear.
  • Threonine and tyrosine kinase (TTK) is a potential target for chemotherapy sensitivity.

Purpose of the Study:

  • Investigate the role of TTK in cisplatin resistance in ovarian cancer.
  • Determine if TTK is a viable therapeutic target for resistant ovarian cancer.

Main Methods:

  • Compared TTK expression in cisplatin-sensitive and resistant ovarian cancer cell lines.
  • Assessed the effect of TTK down-regulation on cisplatin sensitivity.
  • Analyzed the PI3K/AKT signaling pathway in relation to TTK expression.
  • Examined TTK expression in patient tissues with and without cisplatin resistance.

Main Results:

  • TTK expression was significantly higher in cisplatin-resistant ovarian cancer cells.
  • Reducing TTK levels restored sensitivity to cisplatin treatment.
  • The PI3K/AKT pathway was activated in resistant cells and influenced by TTK.
  • High TTK expression correlated with cisplatin resistance in patient tissues.

Conclusions:

  • TTK plays a crucial role in cisplatin resistance in ovarian cancer.
  • Targeting TTK presents a promising therapeutic strategy for overcoming cisplatin resistance.
  • TTK is a potential biomarker for predicting cisplatin resistance in ovarian cancer patients.
Keywords:
Cisplatin resistanceOvarian cancerSignaling pathwayThreonine and tyrosine kinase (TTK)

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.5K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K